NASDAQ: FBRXForte Biosciences Inc Stock
$1.00-0.01 (-0.99%)
Updated Feb 3, 2023
FBRX Price
$1.00
Fair Value Price
$3.33
Market Cap
$21.00M
52 Week Low
$0.90
52 Week High
$1.64
P/E
-1.3x
P/B
0.49x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$12.34M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.05
Operating Cash Flow
-$9M
Beta
1.03
Next Earnings
Mar 29, 2023
Ex-Dividend
N/A
Next Dividend
N/A
FBRX Overview
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Zen Score
–
Industry Average (28)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how FBRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FBRX ($1.00) is undervalued by 69.94% relative to our estimate of its Fair Value price of $3.33 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
FBRX ($1.00) is significantly undervalued by 69.94% relative to our estimate of its Fair Value price of $3.33 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
FBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more FBRX due diligence checks available for Premium users.
Be the first to know about important FBRX news, forecast changes, insider trades & much more!
FBRX News
Valuation
FBRX fair value
Fair Value of FBRX stock based on Discounted Cash Flow (DCF)
Price
$1.00
Fair Value
$3.33
Undervalued by
69.94%
FBRX ($1.00) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
FBRX ($1.00) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
FBRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
FBRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-1.3x
Industry
10.7x
Market
15.09x
FBRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.49x
Industry
5.11x
FBRX is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FBRX's financial health
Profit margin
Revenue
$0.0
Net Income
-$3.4M
Profit Margin
0%
FBRX's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$45.1M
Liabilities
$2.3M
Debt to equity
0.05
FBRX's short-term assets ($44.59M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FBRX's short-term assets ($44.59M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FBRX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
FBRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$1.9M
Investing
$0.0
Financing
$7.4M
FBRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FBRX vs Biotech Stocks
Forte Biosciences Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.